mps vi clinical surveillance program [csp] (BioMarin Inc)
90
Structured Review
BioMarin Inc
mps vi clinical surveillance program [csp]
Mps Vi Clinical Surveillance Program [Csp], supplied by BioMarin Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mps+vi+clinical+surveillance+program+%5Bcsp%5D/mps+vi+clinical+surveillance+program++csp+/pm17671068-220-5-16
Average 90 stars, based on 1 article reviews
Mps Vi Clinical Surveillance Program [Csp], supplied by BioMarin Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mps+vi+clinical+surveillance+program+%5Bcsp%5D/mps+vi+clinical+surveillance+program++csp+/pm17671068-220-5-16
Average 90 stars, based on 1 article reviews
mps vi clinical surveillance program [csp] - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Management guidelines for mucopolysaccharidosis VI. Article Snippet: Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) is a lysosomal storage disease that is characterized by systemic clinical manifestations and significant functional impairment.. Diagnosis and management are often challenging because of the considerable variability in symptom presentation and rate of progression.. The optimal standard of care should be based on evidence from randomized, controlled trials, meta-analyses, systematic reviews, and expert opinion. |